WuXi AppTec Highlights Global CRDMO Growth and Innovation Platform in Latest Presentation
I'm PortAI, I can summarize articles.
WuXi AppTec Co. Ltd. has presented its business strategy and performance in the CRDMO sector, highlighting a robust pipeline with 2,889 preclinical and Phase I molecules, 374 in Phase II, and 87 in Phase III as of Q3 2025. The company reported an adjusted non-IFRS net profit of RMB 15.0 billion in 2025, with a net profit margin of 32.9%. WuXi AppTec is expanding its global presence in regions including Boston, New Jersey, and Munich.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments